Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Receptos Initiates SUNBEAM Phase 3 Trial of RPC1063 in Relapsing Multiple Sclerosis
More to come: humoral immune responses in MS.
Phase 3 Study of RPC1063 in Relapsing MS
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders.
Takeda Pharmaceutical: New Drug Application Approval in Japan for Copaxone® Subcutaneous Injection 20 mg Syringe, a Drug for the Treatment of Multiple Sclerosis
Daclizumab Therapy for Multiple Sclerosis.
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis.
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Daclizumab-induced adverse events in multiple organ systems in multiple sclerosis.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
BTG plc Close Period Update
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
The Clinical Meaning of Walking Speed as Measured by the Timed 25-Foot Walk in Patients With Multiple Sclerosis.
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)

Pages